Epigenome Editing Technologies for Discovery and Medicine

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2024 Jul 29

PMID 39075148

Authors

Sean R McCutcheon

Dahlia Rohm

Nahid Iglesias

Charles A Gersbach

Affiliations

Soon will be listed here.

Abstract

Epigenome editing has rapidly evolved in recent years, with diverse applications that include elucidating gene regulation mechanisms, annotating coding and noncoding genome functions and programming cell state and lineage specification. Importantly, given the ubiquitous role of epigenetics in complex phenotypes, epigenome editing has unique potential to impact a broad spectrum of diseases. By leveraging powerful DNA-targeting technologies, such as CRISPR, epigenome editing exploits the heritable and reversible mechanisms of epigenetics to alter gene expression without introducing DNA breaks, inducing DNA damage or relying on DNA repair pathways.

Citing Articles

Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.

Megdiche Y, Salerno-Goncalves R Front Immunol. 2025; 16:1547213.

PMID: 40040700 PMC: 11876029. DOI: 10.3389/fimmu.2025.1547213.

Designer mammalian living materials through genetic engineering.

Gameiro M, Almeida-Pinto J, Moura B, Mano J, Gaspar V Bioact Mater. 2025; 48:135-148.

PMID: 40034809 PMC: 11872553. DOI: 10.1016/j.bioactmat.2025.02.007.

Epigenetic editing of PCSK9 for a durable reduction in cholesterol.

Nat Med. 2025; .

PMID: 40000801 DOI: 10.1038/s41591-025-03583-0.

Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing.

Rohm D, Black J, McCutcheon S, Barrera A, Berry S, Morone D Cell Genom. 2025; 5(2):100770.

PMID: 39947136 PMC: 11872474. DOI: 10.1016/j.xgen.2025.100770.

Characterization of Rationally Designed CRISPR/Cas9-Based DNA Methyltransferases with Distinct Methyltransferase and Gene Silencing Activities in Human Cell Lines and Primary Human T Cells.

Guerra-Resendez R, Lydon S, Ma A, Bedford G, Reed D, Kim S ACS Synth Biol. 2025; 14(2):384-397.

PMID: 39898483 PMC: 11854388. DOI: 10.1021/acssynbio.4c00569.

References

Luo Y, Hitz B, Gabdank I, Hilton J, Kagda M, Lam B . New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. Nucleic Acids Res. 2019; 48(D1):D882-D889. PMC: 7061942. DOI: 10.1093/nar/gkz1062. View

Gersbach C, Gaj T, Barbas 3rd C . Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Acc Chem Res. 2014; 47(8):2309-18. PMC: 4139171. DOI: 10.1021/ar500039w. View

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna J, Charpentier E . A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096):816-21. PMC: 6286148. DOI: 10.1126/science.1225829. View

Cong L, Ran F, Cox D, Lin S, Barretto R, Habib N . Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339(6121):819-23. PMC: 3795411. DOI: 10.1126/science.1231143. View

Mali P, Yang L, Esvelt K, Aach J, Guell M, DiCarlo J . RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121):823-6. PMC: 3712628. DOI: 10.1126/science.1232033. View

Qi L, Larson M, Gilbert L, Doudna J, Weissman J, Arkin A . Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013; 152(5):1173-83. PMC: 3664290. DOI: 10.1016/j.cell.2013.02.022. View

Anzalone A, Koblan L, Liu D . Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020; 38(7):824-844. DOI: 10.1038/s41587-020-0561-9. View

Porto E, Komor A, Slaymaker I, Yeo G . Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020; 19(12):839-859. PMC: 7721651. DOI: 10.1038/s41573-020-0084-6. View

Zhao Z, Shang P, Mohanraju P, Geijsen N . Prime editing: advances and therapeutic applications. Trends Biotechnol. 2023; 41(8):1000-1012. DOI: 10.1016/j.tibtech.2023.03.004. View

10.

Fischle W, Wang Y, Allis C . Histone and chromatin cross-talk. Curr Opin Cell Biol. 2003; 15(2):172-83. DOI: 10.1016/s0955-0674(03)00013-9. View

11.

Esteller M . Epigenetics in cancer. N Engl J Med. 2008; 358(11):1148-59. DOI: 10.1056/NEJMra072067. View

12.

Feinberg A . Phenotypic plasticity and the epigenetics of human disease. Nature. 2007; 447(7143):433-40. DOI: 10.1038/nature05919. View

13.

Cheng A, Wang H, Yang H, Shi L, Katz Y, Theunissen T . Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013; 23(10):1163-71. PMC: 3790238. DOI: 10.1038/cr.2013.122. View

14.

Maeder M, Linder S, Cascio V, Fu Y, Ho Q, Joung J . CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10(10):977-9. PMC: 3794058. DOI: 10.1038/nmeth.2598. View

15.

Hilton I, DIppolito A, Vockley C, Thakore P, Crawford G, Reddy T . Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol. 2015; 33(5):510-7. PMC: 4430400. DOI: 10.1038/nbt.3199. View

16.

Thakore P, DIppolito A, Song L, Safi A, Shivakumar N, Kabadi A . Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods. 2015; 12(12):1143-9. PMC: 4666778. DOI: 10.1038/nmeth.3630. View

17.

Schmidt R, Steinhart Z, Layeghi M, Freimer J, Bueno R, Nguyen V . CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science. 2022; 375(6580):eabj4008. PMC: 9307090. DOI: 10.1126/science.abj4008. View

18.

Klann T, Black J, Chellappan M, Safi A, Song L, Hilton I . CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol. 2017; 35(6):561-568. PMC: 5462860. DOI: 10.1038/nbt.3853. View

19.

Gilbert L, Larson M, Morsut L, Liu Z, Brar G, Torres S . CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154(2):442-51. PMC: 3770145. DOI: 10.1016/j.cell.2013.06.044. View

20.

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View